Cytokinetics (CYTK) is moving sharply higher today after announcing positive topline results from ACACIA-HCM, its pivotal Phase 3 study of aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM). The company said the trial met both dual primary endpoints, with statistically significant improvements from baseline to Week 36 versus placebo in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) and maximal exercise performance (peak VO2). (ir.cytokinetics.com)

Beyond the dual primary endpoints, the company reported statistically significant improvements across key secondary endpoints including NYHA functional class, a composite CPET z-score, and NT-proBNP. On safety, Cytokinetics said no new safety signals were identified; however, LVEF <50% occurred in 10% of participants on aficamten versus 1% on placebo, with two serious heart-failure events associated with LVEF <50% in the aficamten arm and treatment interruptions due to LVEF <40% in 3% of participants. (ir.cytokinetics.com)

Non-obstructive HCM has had no approved therapies that address underlying hypercontractility, making ACACIA-HCM’s positive readout a potential path to an additional aficamten indication and a materially larger commercial runway. The company also highlighted plans to present detailed data at an upcoming medical meeting and to discuss the results with the FDA and other regulators, setting up a clearer regulatory roadmap for a potential label expansion. (ir.cytokinetics.com)

Cytokinetics is hosting an investor conference call and webcast on May 5, 2026 at 8:00 a.m. ET to discuss the topline ACACIA-HCM results, which could further shape expectations around filing timing, trial details, and the risk/benefit profile investors will focus on (especially LVEF-related findings). (ir.cytokinetics.com)